The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index; 14 of the 24 sources its claims cite were checked for support.
Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial
Open accessAbstract
Aim: To evaluate the activity and safety of the PD-1 antibody pembrolizumab in adult patients with advanced osteosarcoma. Material and methods: The study was a single-arm, open-label, phase 2 trial in patients with unresectable, relapsed osteosarcoma. The primary endpoint was clinical benefit rate (CBR) at 18 weeks of treatment, defined as complete response, partial response, or stable disease using RECIST v1.1. The trial had a Simon´s two-stage design, and ≥ 3 of 12 patients with clinical benefit in stage 1 were required to proceed to stage 2. The trial is registered with ClinicalTrials.gov, number NCT03013127. NanoString analysis was performed to explore tumor gene expression signatures and pathways. Results: Twelve patients were enrolled and received study treatment. No patients had clinical benefit at 18 weeks of treatment, and patient enrollment was stopped after completion of stage 1. Estimated median progression-free survival was 1.7 months (95% CI 1.2–2.2). At time of data cut-off, 11 patients were deceased due to osteosarcoma. Median overall survival was 6.6 months (95% CI 3.8–9.3). No treatment-related deaths or drug-related grade 3 or 4 adverse events were observed. PD-L1 expression was positive in one of 11 evaluable tumor samples, and the positive sample was from a patient with a mixed treatment response. Conclusion: In this phase 2 study in advanced osteosarcoma, pembrolizumab was well-tolerated but did not show clinically significant antitumor activity. Future trials with immunomodulatory agents in osteosarcoma should explore combination strategies in patients selected based on molecular profiles associated with response.
Overview
CoChat Summary
TL;DR
In this single-arm phase 2 trial, pembrolizumab was well tolerated but showed no clinically significant antitumor activity in adults with advanced osteosarcoma. Enrollment stopped after stage 1 because none of 12 patients achieved clinical benefit at 18 weeks.
Key findings
- No patients had clinical benefit (CR, PR, or SD) at 18 weeks; 0 of 12 reached the primary endpoint, so the Simon two-stage trial did not proceed to stage 2.
- Estimated median progression-free survival was 1.7 months (95% CI 1.2–2.2), and median overall survival was 6.6 months (95% CI 3.8–9.3); 11 patients were deceased due to osteosarcoma at data cut-off.
- Adverse events of grade 3 or higher occurred in 7 of 12 patients (58%), but no treatment-related deaths or drug-related grade 3 or 4 adverse reactions were observed.
- PD-L1 expression was positive in 1 of 11 evaluable tumor samples; that patient had a mixed radiological and metabolic response, with reduction in lung and kidney metastases but progression of abdominal and pelvic metastases.
Methods
- Single-arm, open-label, phase 2 trial (PROMO; NCT03013127) in patients aged ≥18 years with unresectable, relapsed osteosarcoma; 12 patients were enrolled across two sites between May 31, 2017, and Sept 27, 2018.
- Pembrolizumab 200 mg was given intravenously every 21 days; primary endpoint was clinical benefit rate at 18 weeks by RECIST v1.1, with secondary endpoints including PFS, OS, ORR, PET/CT response, quality of life, safety, and tolerability.
- Exploratory analyses included PD-L1 immunohistochemistry (clone 22C3) and NanoString PanCancer IO 360 gene expression profiling on available fresh frozen tissue.
Limitations
- The paper states that due to rapid disease progression, only four patients completed EORTC QLQ-C30 questionnaires during treatment, so quality of life results are not reported.
- The trial stopped after stage 1 with only 12 patients, limiting statistical precision and preventing evaluation of the planned stage 2 population.
- Evident from the text: this was a single-arm study without a control group, and the molecular analyses were exploratory and based on small available sample numbers (11 PD-L1 samples, 6 fresh frozen samples), so no definitive predictive conclusions can be drawn.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
11 Valid · 0 Not valid · 2 Not checked · 23 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The prognosis for patients with recurrent osteosarcoma is poor [1–4].”
§ Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial > Introduction
What the sources say
- Supportedcites [1] Bacci G, Briccoli A, Longhi A, Ferrari S, Mercuri M, Fagioli F et al (2005) Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. Acta Oncol 44(7):748–755. https://doi.org/10.1080/02841860500327503 source
The outcome summary reports 28.8% five-year post-relapse overall survival, and the Discussion concludes that prolonged survival or cure is possible in about a quarter of cases. These findings support the broad statement that prognosis after recurrence is poor. Page numbers are not provided in our copy. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [2] Bielack SS, Kempf-Bielack B, Branscheid D, Carrle D, Friedel G, Helmke K et al (2009) Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients. J Clin Oncol 27(4):557–565. https://doi.org/10.1200/JCO.2008.16.2305 source
- Not checked — no full text of the sourcecites [3] Saeter G, Hoie J, Stenwig AE, Johansson AK, Hannisdal E, Solheim OP (1995) Systemic relapse of patients with osteogenic sarcoma. prognostic factors for long term survival. Cancer 75(5):1084–1093 doi:10.1002/1097-0142(19950301)75:5
- Not checked — no full text of the sourcecites [4] Tirtei E, Asaftei SD, Manicone R, Cesari M, Paioli A, Rocca M et al (2018) Survival after second and subsequent recurrences in osteosarcoma: a retrospective multicenter analysis. Tumori 104(3):202–206. https://doi.org/10.1177/0300891617753257 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Tumor-intrinsic signaling through these pathways is associated with an immunosuppressive microenvironment and low T-cell infiltration [20, 21].”
§ Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial > Discussion
What the sources say
- Supportedcites [20] Li X, Xiang Y, Li F, Yin C, Li B, Ke X (2019) WNT/beta-catenin signaling pathway regulating T cell-inflammation in the tumor microenvironment. Front Immunol 10:2293. https://doi.org/10.3389/fimmu.2019.02293 source
The citation is one of two attached to a claim about TGF-β and Wnt pathways; this source supports the Wnt component. The “WNT Signaling and Immunosurveillance in the TME” section describes tumor-intrinsic β-catenin signaling that excludes T cells and impairs antitumor immune responses. (LLM, conf=0.90)
- Partly supportedcites [21] Lind H, Gameiro SR, Jochems C, Donahue RN, Strauss J, Gulley JM, et al. (2020) Dual targeting of TGF-beta and PD-L1 via a bifunctional anti-PD-L1/TGF-betaRII agent: status of preclinical and clinical advances. J Immunother Cancer 8:1. doi: https://doi.org/10.1136/jitc-2019-000433 sourceExperimental — accuracy not yet measured
The Introduction (page not provided) says TGF-β can suppress antitumor immune responses, supporting the immunosuppressive aspect of the claim. The copy does not establish that tumor-intrinsic TGF-β or Wnt signaling is associated with low T-cell infiltration; searches for Wnt and T-cell exclusion did not find that combined claim in the paper’s discussion. (LLM, conf=0.85)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Although the overall predictive value of PD-L1 expression is uncertain in soft tissue sarcoma [19], the two patients with PD-L1 expression > 1% who were evaluable for response in the SARC028 trial had objective and durable responses.”
§ Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial > Discussion
What the sources say
- Supportedcites [13] Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J et al (2017) Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol 18(11):1493–1501. https://doi.org/10.1016/S1470-2045(17)30624-1 source
The Results report that, of three pretreatment samples positive for PD-L1 at the 1% threshold, two patients were evaluable for response: one had a complete response and the other a partial response. The Results also describe the UPS complete response as lasting more than 13 months and the UPS partial responses as durable; both PD-L1-positive responders had UPS. (LLM, conf=0.91)
plainstates an associationn = 2- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A recent and comprehensive characterization of the immuno-genomic landscape of osteosarcoma suggests that the majority of osteosarcomas are “cold” tumors, with low levels of immune cell infiltration, low-to-moderate tumor mutation burden and lack of neoantigen expression [24].”
§ Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial > Discussion
What the sources say
- Partly supportedcites [24] Wu CC, Beird HC, Andrew Livingston J, Advani S, Mitra A, Cao S et al (2020) Immuno-genomic landscape of osteosarcoma. Nat Commun 11(1):1008. https://doi.org/10.1038/s41467-020-14646-w sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, a French study with metronomic cyclophosphamide and pembrolizumab reported partial response (PR) in one of 14 evaluable patients [17].”
§ Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial > Introduction
What the sources say
- Supportedcites [17] Le Cesne A, Marec-Berard P, Blay JY, Gaspar N, Bertucci F, Penel N et al (2019) Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study. Eur J Cancer 119:151–157. https://doi.org/10.1016/j.ejca.2019.07.018 source
The Results report one partial response and identify 14 patients with centrally reviewed imaging (Figure 2A). They distinguish this group from the 15 patients assessable for the primary efficacy analysis, one of whom had no tumour imaging evaluation. The study was conducted at French centres and used pembrolizumab with metronomic cyclophosphamide. (LLM, conf=0.90)
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
18 more claims · 1 with their cited sources checked
Create a free account to see all 36 claims and every source verdict.
- It may state two separate claims as one. 9
- Probably not a substantial claim. 5
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The results demonstrated that pembrolizumab was well tolerated but did not show clinical benefit [86].”
From Advances on immunotherapy for osteosarcoma (2024) · cites this paper as [86]
Citations
Cites
B cells are associated with survival and immunotherapy response in sarcoma
Petitprez, F., de Reyniès, A., Keung, E. Z., Chen, T. W.-W., Sun, C.-M., Calderaro, J., Jeng, Y.-M., Hsiao, L.-P., Lacroix, L., Bougoüin, A., et al. (2020) · Nature · doi:10.1038/s41586-019-1906-8 · Cited by 1,942
Tawbi, H. A., Burgess, M., Bolejack, V., Van Tine, B. A., Schuetze, S. M., Hu, J., D'Angelo, S., Attia, S., Riedel, R. F., Priebat, D. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30624-1 · Cited by 1,452 · cited 3×
“In SARC028, only three of 70 evaluable samples were PD-L1 positive, all of which were undifferentiated pleomorphic sarcomas [13].”
BackgroundInfluentialDe-novo and acquired resistance to immune checkpoint targeting
Syn, N. L., Teng, M. W. L., Mok, T. S. K., & Soo, R. A. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30607-1 · Cited by 662 · cited 1×
“Several mechanisms might explain the observed primary resistance, including lack of recognition by the adaptive immune system, insensitivity to the antiproliferative and proapoptotic effects of T-cell effector molecules, and an immunosuppressive microenvironment [22, 23].”
BackgroundKempf-Bielack, B., Bielack, S. S., Jürgens, H., Branscheid, D., Berdel, W. E., Exner, G. U., Göbel, U., Helmke, K., Jundt, G., Kabisch, H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.063 · Cited by 643 · cited 1×
“1 3 in second and later lines seems to produce a limited prolongation in survival [11, 12], and new therapeutic approaches are needed.”
BackgroundCasali, P. G., Bielack, S., Abecassis, N., Aro, H. T., Bauer, S., Biagini, R., Bonvalot, S., Boukovinas, I., Bovee, J. V. M. G., Brennan, B., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy310 · Cited by 617 · cited 1×
“Second-line systemic treatment options include ifosfamide and etoposide with or without carboplatin, high-dose ifosfamide alone, or gemcitabine-based regimens [5, 6].”
BackgroundSelf-citationGeoerger, B., Kang, H. J., Yalon-Oren, M., Marshall, L. V., Vezina, C., Pappo, A., Laetsch, T. W., Petrilli, A. S., Ebinger, M., Toporski, J., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30671-0 · Cited by 357
Davis, K. L., Fox, E., Merchant, M. S., Reid, J. M., Kudgus, R. A., Liu, X., Minard, C. G., Voss, S., Berg, S. L., Weigel, B. J., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30023-1 · Cited by 337
Duffaud, F., Mir, O., Boudou-Rouquette, P., Piperno-Neumann, S., Penel, N., Bompas, E., Delcambre, C., Kalbacher, E., Italiano, A., Collard, O., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30742-3 · Cited by 331
Italiano, A., Mir, O., Mathoulin-Pelissier, S., Penel, N., Piperno-Neumann, S., Bompas, E., Chevreau, C., Duffaud, F., Entz-Werlé, N., Saada, E., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30825-3 · Cited by 326
Postrelapse Survival in Osteosarcoma of the Extremities: Prognostic Factors for Long-Term Survival
Ferrari, S., Briccoli, A., Mercuri, M., Bertoni, F., Picci, P., Tienghi, A., Del Prever, A. B., Fagioli, F., Comandone, A., & Bacci, G. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.141 · Cited by 316 · cited 1×
“1 3 in second and later lines seems to produce a limited prolongation in survival [11, 12], and new therapeutic approaches are needed.”
Background
Cited by
Advances on immunotherapy for osteosarcoma
Yu, S., & Yao, X. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02105-9 · Cited by 270
“The results demonstrated that pembrolizumab was well tolerated but did not show clinical benefit [86].”
BackgroundInvasion and metastasis in cancer: molecular insights and therapeutic targets
Li, Y., Liu, F., Cai, Q., Deng, L., Ouyang, Q., Zhang, X. H.-F., & Zheng, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02148-4 · Cited by 244
“314 Following anti-angiogenic therapy for metastatic clear cell RCC, patients with bone metastasis treated with nivolumab exhibited a poorer prognosis with lower PFS and objective response rates.”
Recent and Ongoing Research into Metastatic Osteosarcoma Treatments
Harris, M. A., & Hawkins, C. J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073817 · Cited by 159
Panez-Toro, I., Muñoz-García, J., Vargas-Franco, J. W., Renodon‐Cornière, A., Heymann, M., Lézot, F., & Heymann, D. (2023) · Current Osteoporosis Reports · doi:10.1007/s11914-023-00803-9 · Cited by 143
Immune checkpoints in osteosarcoma: Recent advances and therapeutic potential
Yang, W., Tang, F., Tu, C., Hornicek, F. J., Duan, Z., & Min, L. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215887 · Cited by 114
Metadata
- Authors
- Boye, K., Longhi, A., Guren, T., Lorenz, S., Næss, S., Pierini, M., Taksdal, I., Lobmaier, I., Cesari, M., Paioli, A., Løndalen, A. M., Setola, E., Hompland, I., Meza-Zepeda, L. A., Sundby Hall, K., & Palmerini, E.
- Affiliations
- Oslo University Hospital (NO)
- Istituto Ortopedico Rizzoli (IT)
- Corresponding author
- Boye, Kjetil
- ORCID
- Venue
- Cancer Immunology, Immunotherapy
- Published
- 2021-02-12
- Volume
- 70
- Issue
- 9
- Pages
- 2617-2624
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- PMC
- PMC8360887
- OpenAlex
- W3128411524
- Semantic Scholar
- b9e8f55f491344d256da12648a80217425b3f72a
- Cited by
- 112
- References
- 27
- Citations by year
- 2026: 19 · 2025: 27 · 2024: 16 · 2023: 22 · 2022: 21 · 2021: 6
- FWCI
- 10.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Cancer Immunology Immunotherapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, other-oa)
- Funders
- The Radium Hospital Foundation
- Oslo University Hospital Trust
- Merck Sharp and Dohme
- University of Oslo
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
- Keywords
- pembrolizumab, PD-1 inhibitors, PD-L1 expression, relapsed osteosarcoma, anticancer activity, treatment safety, immunotherapy
- MeSH terms
- Positron Emission Tomography Computed Tomography, Immune Checkpoint Inhibitors, Bone Neoplasms, Combined Modality Therapy, Humans, Neoplasm Metastasis, Neoplasm Staging, Osteosarcoma, Biomarkers, Tumor, Treatment Outcome, Fluorodeoxyglucose F18, Gene Expression Profiling, B7-H1 Antigen, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial. https://app.cochat.ai/papers/10.1007/s00262-021-02876-w
- The paper
- Boye, K., Longhi, A., Guren, T., Lorenz, S., Næss, S., Pierini, M., Taksdal, I., Lobmaier, I., Cesari, M., Paioli, A., Løndalen, A. M., Setola, E., Hompland, I., Meza-Zepeda, L. A., Sundby Hall, K., & Palmerini, E. (2021). Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-021-02876-w
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.